Navigation Links
More Research Points to Long-Term Ills With Bone Drugs
Date:5/21/2012

MONDAY, May 21 (HealthDay News) -- Adding more weight to concerns about possible long-term dangers of osteoporosis drugs, a new study finds that people who take the drugs, known as bisphosphonates, may be at increased risk for atypical fractures of the thigh bone (femur).

Osteoporosis is a bone-thinning disease that is common in older women. An atypical femoral fracture is an unusual type of break that often occurs spontaneously, without any major leg injury.

In the new study, Swiss researchers looked at 477 patients, aged 50 and older, who were hospitalized with a femoral fracture. Of those patients, 39 had atypical fractures and 438 had a classic fracture (a more common fracture with a typical pattern).

These groups were compared with 200 people without femoral fractures. The findings were published online May 21 in the journal Archives of Internal Medicine.

The investigators found that 82 percent of the patients with atypical fractures had been treated with bisphosphonates, such as Actonel or Fosamax, compared with about 6 percent of the patients with classic fractures.

But compared to patients without fractures, use of bisphosphonates was associated with a 47 percent reduction in the risk of a classic fracture.

The researchers compared duration of bisphosphonate treatment versus no treatment and found that the odds ratio for an atypical fracture versus a classic fracture was 35 to 1 for less than two years of treatment, 46 to 9 for two to five years of treatment, 117 to 1 for five to nine years of treatment, and 175 to 7 for more than nine years of treatment.

"In conclusion, we have demonstrated that the association between bisphosphonate treatment and the occurrence of atypical fractures of the femur is highly likely and that the duration of such treatment significantly correlates with augmented risk," Dr. Raphael Meier and colleagues from University Hospitals of Geneva and Faculty of Medicine in Geneva, concluded in a journal news release.

"However, the incidence rate was very low, and the absolute benefit to risk ratio of bisphosphonate use remains positive," the authors added.

While the study uncovered an association between bisphosphonate use and atypical fractures, it did not prove a cause-and-effect relationship.

In 2010, the U.S. Food and Drug Administration issued a warning about the possible risk of femur fractures from taking bisphosphonates over a long period of time.

More information

The National Osteoporosis Foundation has more about osteoporosis medicines.

-- Robert Preidt

SOURCE: Archives of Internal Medicine, news release, May 21, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kessler Foundation scientists present cognitive research findings at MS dual symposium
2. AGA presents cutting-edge research during DDW®
3. Research With Dogs Points to Early Test for Arthritis
4. Dartmouth researchers investigate the cognitive effects of athlete head impacts
5. Fish Pedicure a Recipe for Bacterial Infection, Researchers Warn
6. Fox Chase researchers find no disparities in imaging before breast cancer surgery
7. More cutting-edge cancer research supported by industry
8. Mount Sinai presents treatment trends, vaccine research, prognosis data at ASCO
9. Researchers undertake radical new cancer survivorship study
10. Parents are happier than non-parents, new research suggests
11. Researchers make promising discovery in pursuit of effective lymphoma treatments
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
More Research Points to Long-Term Ills With Bone Drugs
(Date:6/20/2017)... ... June 20, 2017 , ... In his newly appointed role ... May, Ph.D., recently accepted the distinguished Sun Corridor Export Award for his company’s ... (WNB), and 16 other businesses from Pima, Pinal, and Maricopa counties in Arizona, ...
(Date:6/20/2017)... West Hempstead, NY (PRWEB) , ... June 20, ... ... most experienced in the security systems industry has been selected as the partner ... , Amtrak is a passenger railroad service that provides medium- and long-distance intercity ...
(Date:6/20/2017)... ... 2017 , ... John D'Eri, CEO of Rising Tide Car Wash , ... during the Autism Society of America 's 49th annual conference to be ... Foundation (DJFF) was founded in 2002 as the nation's first autism organization focused ...
(Date:6/20/2017)... ... June 20, 2017 , ... MEDI+SIGN, ... like to officially welcome Anthony Stanowski, DHA, FACHE to the MEDI+SIGN Advisory Board. ... and expertise in healthcare will provide invaluable direction for the company,” says Andrew ...
(Date:6/20/2017)... ... , ... The law firm of Momkus McCluskey Roberts LLC congratulates ... DuPage County Bar Association’s Board of Directors. Cassioppi officially took on the leadership role ... Oak Brook. Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was also installed as ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... , June 1, 2017 Nutriceutical Holdings (NH), ... Recommended Solutions (VRS), and KD Pharma Group have decided ... Holdings by KD Pharma Group. KD Pharma Group will ... option to acquire the entire company. "We ... They are committed to growing the NH companies by ...
(Date:5/26/2017)... -- Endo International plc (NASDAQ: ENDP ) announced today ... the Company in a fireside chat at Goldman Sachs, 38 ... 2017 at 10:40 a.m. PT / 1:40 p.m. ET. The ... Rancho Palos Verdes, CA. A live ... on the Company,s website at http://www.endo.com/investors/overview . Participants should ...
(Date:5/22/2017)... 22, 2017  As the specialty pharmacy industry ... to make the revolutionary shift from volume-based to ... ensuring positive patient outcomes and shaping the future ... focus away from clinical trials and toward data ... specialty drug therapy utilization in precise patient populations. ...
Breaking Medicine Technology: